Amsacrine alone or in combination with 5-azacytidine and etoposide in refractory or relapsed acute non lymphoblastic leukemia (ANLL).
A M
AM
Carella
G
G
Santini
M
M
Martinengo
S
S
Nati
D
D
Giordano
A
A
Congiu
R
R
Cerri
E
E
Damasio
M
M
Risso
E
E
Rossi
D000208:Acute Disease; D000609:Aminoacridines / Q000008:administration & dosage / Q000627:therapeutic use* / Q000633:toxicity; D000677:Amsacrine; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D005047:Etoposide / Q000008:administration & dosage*; D006801:Humans; D007938:Leukemia / Q000188:drug therapy*; D011034:Podophyllotoxin / Q000031:analogs & derivatives*
D000609:Aminoacridines; D000970:Antineoplastic Agents; D000677:Amsacrine; D005047:Etoposide; D011034:Podophyllotoxin; D001374:Azacitidine